# The conversation

Every prompt Alex gave, and what Claude did in response — up to this commit and no
further. Check out an earlier tag and this file rewinds with it.

Phases: **R**esearch · **P**lan · **E**xecute · ⟲ **R**eflect

---

## R · Research — read the paper, keep only what is reproducible
`01-research` · 2026-07-24 18:14

**Alex:**
> read through the following paper that used various genetic datasets and used mendelian randomization to ascertain the effect of lifelong lipid lowering through genetics on risk of alzheimers. The notes should include only facts that are needed in order to reproduce this paper's approach using the datasets that can publically downloaded without request. The reproduction would not need to be perfect as it would be for a workshop tutorial, but should be able to ask a similar question and perform similar methods. Only include facts, not opinions in the research.md file

**What Claude did**

1. Searched the working directory, found the paper (`ALZ-21-e70638.pdf`) without being told where it was.
2. Had no PDF text extractor available — probed for `PyPDF2`, then `pypdf`, then `fitz`, and used the one that was installed to dump the full text to a scratch file.
3. Read the whole paper, then re-read the back matter specifically for data-availability statements and variant identifiers.
4. Audited every data source against the constraint in the prompt — *downloadable without a request* — and found only **2 of 5** qualify.
5. Wrote `research.md` as facts only: sources, download URLs, genome build, the six drug-target genes with their variants, instrument-selection rules, and the paper's own published numbers to check against.

**The finding that shaped everything downstream**

The paper has three analysis arms. Two of them (Cox regression, one-sample MR) run on **UK Biobank** and **Copenhagen CGPS/CCHS** — application-gated, and Danish law forbids sharing the Copenhagen data outright. Only the **two-sample MR** arm is reproducible, on **GLGC** (lipid GWAS → exposure) × **FinnGen** (dementia/IHD GWAS → outcome).

That constraint was discovered in the Research phase, not the Execute phase — which is the point of having one.

**Files:** `research.md`

---

## P · Plan — align before writing any code
`02-plan` · 2026-07-24 18:32

**Alex:**
> read through the research.md and come up with a phased plan.md file to reproduce findings using the 2 available dataset. phases should first "make it work" then "make it right". iterate for open questions on what is to be done and how it is to be done, ask me so that we achieve alignment on the plan before any implementation. continue to iterate until it make sense and challenge me if my choices dont make sense to you

**What Claude did**

1. Read `research.md`, then read the sibling project's `plan.md` to pick up house conventions rather than inventing a format.
2. **Stopped and asked**, instead of guessing, on four forks that genuinely change the shape of the plan:

| Question | Options | Alex chose |
|---|---|---|
| Language / tooling | R + `TwoSampleMR` · Python hand-rolled · Python calling R | **R + TwoSampleMR** |
| Data + LD clumping | Local files + local LD panel · OpenGWAS API · hybrid | **Local files + local LD panel** |
| Instrument selection | De-novo · paper's exact rsIDs · **rsIDs for MVP, de-novo later** | **rsIDs for MVP, de-novo later** |
| Phase 1 "done" bar | non-HDL → dementia + IHD, 6 genes · IHD only · full grid | **non-HDL → dementia + IHD, 6 genes** |

3. Flagged one consequence of Alex's instrument choice up front: because Phase 1 uses hardcoded rsIDs, **Phase 1 needs no LD clumping at all** — so the 1000G LD panel is a Phase-2 dependency, not a Phase-1 blocker. Staged in Phase 0, but off the hot path.
4. Named four residual defaults as veto-able rather than silently adopting them: latest FinnGen release, 1000G Phase 3 EUR panel, drop ambiguous palindromes at harmonization, no cross-cohort meta-analysis.
5. Wrote `plan.md`: Phase 0 acquire → Phase 1 make it work → Phase 2 make it right → Phase 3 stretch.

**Three things baked in as design decisions, not defaults**

- A loud "these ORs will **not** match the paper" framing — FinnGen-only outcome vs. the paper's pooled meta-analysis, and per-SD vs per-mmol/L units.
- A **palindromic-SNP guard** as a named failure mode: for single-SNP targets, one dropped ambiguous SNP silently kills the whole gene, so it must be logged, never blanked.
- The **IHD positive control is the exit gate** for Phase 1 — if lipid lowering doesn't look protective for heart disease, no dementia estimate is trustworthy.

**Files:** `plan.md`

---

## E · Execute — Phase 0: get the bytes
`03-execute-phase0-scaffold` · 2026-07-24 18:39

**Alex:**
> agreed proceed

**What Claude did**

1. Probed the environment *before* scaffolding: R 4.5.0 present, network up, `plink` missing (Phase-2 only — deferred, per the plan).
2. Kicked off the slow `TwoSampleMR` + `ieugwasr` GitHub installs **in the background** and probed the real data endpoints meanwhile, instead of waiting serially.
3. Found the GLGC file listing and confirmed the `without_UKB_*_EUR_*` variants exist — exactly the non-UK-Biobank European set the paper used.
4. **Discovered the fact that reshaped Phase 0.** The GLGC files are 1.4–1.8 GB gzipped each (~5 GB for all three) — but they are **bgzipped with `.tbi` tabix indexes**. So the six cis-gene windows could be pulled *remotely* with `tabix`, without downloading the gigabytes. Same for FinnGen.
5. Installed `htslib` via Homebrew for `tabix`, walked the FinnGen public GCS bucket to get exact endpoint names (the correct prefix turned out to be `summary_stats/release/`, not the one first guessed), and verified a live remote region query against both sources.
6. Confirmed the column formats and effect-allele conventions for each source, and noted the build mismatch: **GLGC is hg19, FinnGen R12 is hg38** — so the tabix windows differ by build, but harmonization is by rsID + alleles, so Phase 1 is unaffected.
7. Wrote `config.R` (genes, windows, rsIDs, endpoints), `src/download.R` (one tabix call per file, all six windows at once), and `.gitignore`.

**Why this mattered:** the plan said "download the data." The environment said there was a cheaper way. Remote `tabix` turned a 5 GB download into ~10k variants per file — fast, and offline after the first fetch.

**Files:** `config.R`, `src/download.R`, `.gitignore`

---

## E · Execute — Phase 0 complete: data cached
`04-execute-phase0-data` · 2026-07-24 18:41

*(no new prompt — continuing from "agreed proceed")*

**What Claude did**

1. Ran `Rscript src/download.R`.
2. All 10 instrument rsIDs landed; every FinnGen endpoint extracted 10,824 variants across the six cis windows.
3. Wrote `results/endpoints.md` documenting the exact FinnGen R12 phenocodes used:
   - all-cause dementia → `F5_DEMENTIA`
   - Alzheimer's → `G6_ALZHEIMER`
   - vascular dementia → `F5_VASCDEM`
   - IHD (positive control) → `I9_IHD`

   Unspecified dementia has no clean standalone public endpoint — recorded as a known Phase-2 concern rather than quietly dropped.

**Files:** `results/endpoints.md`

---

## E · Execute — Phase 1: make it work
`05-execute-phase1` · 2026-07-24 18:42

*(no new prompt — continuing)*

**What Claude did**

Built the Phase-1 pipeline as four small modules plus a driver, matching the plan exactly:

- `src/exposure.R` — read cached GLGC cis windows, keep the named instrument rsIDs, format as a `TwoSampleMR` exposure
- `src/outcome.R` — read cached FinnGen windows, format as outcome
- `src/mr.R` — harmonize, then Wald ratio (1 SNP) or weighted median (≥3 SNPs), with the palindromic-drop logged
- `run_phase1.R` — 6 genes × {all-cause dementia, IHD}, non-HDL exposure, OR-per-SD table + forest plots

Ran it end to end. **The positive control passed** — all four anti-atherogenic targets protective for IHD — so the dementia estimates were interpretable.

**Files:** `src/exposure.R`, `src/outcome.R`, `src/mr.R`, `run_phase1.R`

---

## ⟲ Reflect — look back at the first run
`06-reflect-phase1-clean` · 2026-07-24 18:44

*(no new prompt — Claude reviewing its own output)*

**What Claude did**

1. Read the run log rather than declaring victory: two warnings were being emitted — a p-value coercion warning in `exposure.R` and a deprecated `ggplot2` call in `run_phase1.R`. Fixed both and re-ran to confirm a clean log.
2. Checked the numbers against the paper's own two-sample results (`research.md` §9) instead of just checking that code ran:

| Target | Outcome | Ours | Paper §9 |
|---|---|---|---|
| HMGCR | IHD | 0.44 (0.31–0.62) | 0.41 (0.30–0.55) |
| ANGPTL4 | IHD | 0.23 (0.14–0.38) | 0.23 (0.15–0.36) |
| PCSK9 | IHD | 0.62 (0.57–0.68) | 0.63 (0.58–0.68) |
| LPL | IHD | 0.44 (0.32–0.61) | 0.48 (0.37–0.62) |
| CETP | IHD | 0.51 (0.43–0.61) | 0.49 (0.40–0.60) |
| PCSK9 | dementia | 1.02 (0.91–1.15) | 1.03 (0.90–1.17) |
| LPL | dementia | 1.70 (1.00–2.89) | 1.60 (1.01–2.55) |

Every direction matched; IHD magnitudes landed almost on top of the paper's, despite being FinnGen-only.

3. Asked Alex how to enter Phase 2 — no-dependency parts first, full Phase 2 including the LD panel, or pause at the milestone. **Alex chose full Phase 2 including the LD panel.**

**Files:** `src/exposure.R`, `run_phase1.R`, `results/mr_phase1.csv`, `results/forest_*.png`

---

## E · Execute — Phase 2: make it right
`07-execute-phase2` · 2026-07-24 18:56

*(continuing from Alex's "Full Phase 2 including LD panel")*

**What Claude did**

1. Started the two slow dependencies **in the background** — `plink`, and the 1.57 GB 1000G EUR LD panel — then built all the code that didn't depend on them while they downloaded.
2. Extended `config.R` with the Phase-2 grid, and `src/mr.R` with the sensitivity estimators (IVW, weighted mode, simple mode, MR-Egger) plus pleiotropy / heterogeneity / F-statistic diagnostics.
3. Wrote `src/instruments.R` — de-novo cis-window selection with local plink clumping (r² ≤ 0.05, F > 10), verified against the paper's named rsIDs.
4. Caught two problems while writing rather than after running:
   - a `rep0` helper that would collide on duplicate argument names — rewritten
   - a **coverage gap in the estimators**: Wald needs exactly 1 SNP and weighted median needs ≥ 3, so a de-novo selection yielding exactly 2 SNPs would fall through both. Added IVW for n = 2.
5. Fetched the LDL and logTG sensitivity exposures, and tightened the run-guard in `src/download.R` so sourcing it elsewhere wouldn't re-trigger extraction.
6. Wrote `run_phase2.R` and `src/write_results.R` (the `RESULTS.md` generator).

**Files:** `config.R`, `src/mr.R`, `src/instruments.R`, `src/download.R`, `run_phase2.R`, `src/write_results.R`

---

## ⟲ Reflect — the bug that only shows up if you read the output
`08-reflect-table-bug` · 2026-07-24 19:02

*(no new prompt — Claude validating its own artifact)*

**What Claude did**

Ran Phase 2, then **actually read the generated `RESULTS.md`** instead of trusting the exit code. Every gene row in the per-outcome tables was duplicated six times — while the estimators table rendered fine.

Traced it: the `fmt` helper in `src/write_results.R` used `ifelse(is.numeric(x), …)`, whose test is length-1, so `ifelse` returned only the first element recycled across the whole column. **Every row rendered as row 1.** All `md_table` output was affected.

Rewrote `md_table` to be vectorization-safe, re-ran, confirmed correct rows.

This is the reflect step earning its place: the pipeline exited 0, the CSVs were right, and the report was silently wrong.

**Files:** `src/write_results.R`

---

## E · Execute — unblock the LD panel path
`09-execute-plink-fix` · 2026-07-24 19:31

*(no new prompt — background task completed)*

**What Claude did**

1. The first LD panel download **failed** — curl exit 28, a 20-minute timeout on a slow mirror at 398 MB of 1.57 GB. Resumed it with `curl -C -`, a longer timeout and retries, in the background. It completed.
2. Then found the real problem: the earlier `brew install plink` had **reported exit 0 but left no binary** — the formula no longer exists in Homebrew. The pipeline would have failed at the clumping step with a confusing error.
3. Fixed it properly rather than working around it: installed `genetics.binaRies`, the R package that ships the exact PLINK 1.9 binary `ieugwasr::ld_clump` expects, and pointed `config.R` at that path.
4. Re-ran with de-novo selection active. Clumping worked — HMGCR: 404 GWAS-significant cis variants → 15 independent at r² ≤ 0.05.

**Files:** `config.R`

---

## ⟲ Reflect — report the honest result, not the flattering one
`10-reflect-honest-recovery` · 2026-07-24 19:33

*(no new prompt — Claude interrogating its own metric)*

**What Claude did**

De-novo selection reported that it "recovered" the paper's named SNPs for only 3 of 6 genes (ANGPTL4, PCSK9, CETP). The easy read is that the reproduction half-failed.

Claude questioned the **metric** instead of the result. The recovery test required the named SNP to be the clump *index* — so a named SNP that is genuinely GWAS-significant but sits next to a stronger variant gets absorbed into that variant's clump and scores as "not recovered." That's a property of clumping, not a reproduction failure.

Changed `src/instruments.R` and `src/write_results.R` to report both facts separately:

- `named_sig` — was the paper's SNP in the GWAS-significant candidate set? → **6 / 6 for every gene**
- clump lead — did it survive as the clump index? → 3 / 6

Both numbers are now in `RESULTS.md`. The de-novo MR still agreed in direction with the curated instruments, and the IHD positive control held under de-novo selection too.

**Files:** `src/instruments.R`, `src/write_results.R`, `results/RESULTS.md`, `results/mr_phase2_*.csv`, `results/instruments_denovo.csv`, `results/forest2_*.png`

---

## ⟲ Reflect — close the loop back to the plan
`11-reflect-plan-annotated` · 2026-07-24 19:35

*(no new prompt)*

**What Claude did**

Went back to `plan.md` and marked Phases 0–2 `✅ DONE`, and updated the repo-layout section to list the files that actually exist rather than the ones that were imagined at planning time.

The plan is the record of intent; leaving it stale makes the next session re-derive what was already decided.

**Summary of the two "make it right" additions:**
- All 4 outcomes × 6 genes, plus LDL/logTG target-specific sensitivity exposures (CETP-via-LDL → IHD 0.33)
- 5 estimators for the multi-SNP genes; MR-Egger appropriately unstable at 3 SNPs — shown, not hidden
- Pleiotropy and heterogeneity diagnostics all clean except PCSK9→IHD (Cochran's Q p = 0.024)

**Files:** `plan.md`

---

## ⟲ Reflect — Alex interrogates the setup (no code changes)
`12-reflect-interrogation` · 2026-07-27 14:41–14:56

Three days later, Alex came back and pushed on the *design* rather than the code. Six questions, no files touched — this whole step is conversation, which is why it exists as its own commit.

**Alex:** *how do i get access to glgc*
> Fully public — no application, no login. Portal at lipidgenetics.org; the actual files live on the Michigan file server this project already pulls from. And you don't need the full 1.5 GB files: Phase 0 already cached exactly the cis windows via remote `tabix`.

**Alex:** *did we exclude UK Biobank like they did?*
> Checked `config.R` rather than answering from memory. **Yes** — all three exposure files are the `without_UKB_*` variants. The reason is sample overlap: the paper pooled UKB on the *outcome* side, so UKB-inclusive GLGC on the exposure side would bias two-sample MR toward the observational estimate.

**Alex:** *since for demo purposes we are not using uk biobank directly does it make sense to include data from uk biobank that are in glgc?*
> Alex's mechanism was right — our outcome is FinnGen, UK Biobank isn't in FinnGen, so there'd be zero overlap and no bias. Claude still argued to **keep** `without_UKB`: the precision gain is invisible (instruments are already F = 62–492; nearly all CI width comes from the outcome side), and it would silently break the moment Phase 3 swaps in a UKB-containing AD GWAS.

**Alex:** *are we using finngen currently or just glgc?*
> **Both**, in different roles — GLGC is the exposure (SNP → lipid), FinnGen the outcome (SNP → disease). Confirmed from what's actually cached on disk, not from memory.

**Alex:** *what is the easiest database to get access to to increase outcome numbers?*
> **IEU OpenGWAS** — free token, minutes to set up, and `TwoSampleMR` reads it natively. The highest-value dataset it exposes is **Bellenguez et al. 2022** (~39k clinical AD cases + proxy) against FinnGen's ~6k. Flagged that this is an **AD-only** lever: all-cause, vascular and unspecified dementia stay FinnGen-dependent.

**Alex:** *is that what the authors used as well?*
> **No** — and this mattered enough to say plainly. `research.md` §2 already flagged Bellenguez/Kunkle/Jansen as *not used by the paper*. Adding them stops being *reproduction* and becomes *extension*: a stronger scientific check (independent replication), but a different question.

**No files changed.** The value of this step is that it reframed Phase 3 from "more power" to "a clearly-labelled extension" — which is how it ended up being built and reported.

---

## E · Execute — Phase 3: the OpenGWAS extension
`13-execute-phase3` · 2026-07-27 14:57

**Alex:**
> i was just trying to understand. lets proceed with opengwas i have the token:
>
> `<OPENGWAS JWT — redacted>`

**What Claude did**

1. **Stored the token safely first**, before using it: written to a gitignored `.Renviron` where `ieugwasr` picks it up as `OPENGWAS_JWT`. Never into tracked code. (`.Renviron` is not in this repo — that is the point.)
2. Verified auth, then resolved the OpenGWAS IDs and confirmed case counts rather than trusting the accession numbers:
   - **Bellenguez 2022** `ebi-a-GCST90027158` — 39,106 clinical AD cases (+ proxy, sample 487k) → primary extension
   - **Kunkle 2019** `ieu-b-2` — 21,982 cases, no UKB, no proxy → the "clean" sensitivity
   Both hg19 / European, matching GLGC.
3. Added an OpenGWAS outcome fetcher to `src/outcome.R` and a raw-effect MR helper to `src/mr.R` (needed for meta-analysis), then wrote `run_phase3.R` and the `write_phase3_md` reporter.
4. **Made a design call that prevents a real statistical error:** Bellenguez 2022 *contains* the Kunkle/IGAP samples, so pooling them would double-count. Only **FinnGen + Bellenguez** (independent) are meta-analyzed; **Kunkle is reported standalone**.
5. Marked Phase 3 done in `plan.md`.

**What it showed** — the power boost landed as predicted:

| Gene | FinnGen (~6k) | Bellenguez (~39k) | Meta |
|---|---|---|---|
| **ANGPTL4** | 2.56 (0.88–7.44) | 2.65 (1.20–5.87) | **2.62 (1.38–4.95), p = 0.003** |
| PCSK9 | 0.92 (0.79–1.07) | 1.11 (0.97–1.27) | 1.02 (0.93–1.13) |
| CETP | 0.82 (0.58–1.17) | 1.13 (0.93–1.39) | 1.05 (0.88–1.25) |

Two caveats surfaced rather than buried: **HMGCR flips harmful only in Kunkle** (2.47, p = 0.036) — a single-SNP Wald estimate that the other two sources contradict; and **LPL dropped in Kunkle** because its instrument `rs328` is a palindrome at intermediate frequency there, so harmonization correctly removed it — *logged, not silently blanked*, exactly the failure mode the plan named on day one.

**Files:** `src/outcome.R`, `src/mr.R`, `run_phase3.R`, `src/write_results.R`, `plan.md`, `results/RESULTS_phase3.md`, `results/mr_phase3_*.csv`, `results/forest_phase3_AD_by_source.png`

---

## E · Execute — the report
`14-execute-report-rmd` · 2026-07-27 15:07

**Alex:**
> put together a report.Rmd

**What Claude did**

1. Wrote `report.Rmd` tying all three phases into one narrative.
2. Made it read the **already-computed** `results/*.csv` and forest PNGs rather than re-running the analysis — so it knits fast and offline, with no plink, no LD panel and no OpenGWAS round-trip at knit time.
3. `pandoc` was missing. Installed it in the background, and meanwhile **validated the R chunks independently** by knitting to markdown (which needs no pandoc) — catching code errors without waiting on the install.
4. Rendered to `report.html` and verified it: all sections present, 3 forest plots embedded, and **grep-confirmed the OpenGWAS token appears zero times in the rendered output**.
5. Marked the report item done in `plan.md`.

**Files:** `report.Rmd`, `report.html`, `plan.md`

---

## ⟲ Reflect — Alex pressure-tests the findings (no code changes)
`15-reflect-findings-challenged` · 2026-07-27 15:23–15:37

Alex read the report and pushed back on the science. Another conversation-only step.

**Alex:** *does the ANGPTL4 result make sense? why are none of the other results significant?*
> Pulled the actual numbers before arguing. Two different answers: the "nothing else is significant" half is a clean **power** story (FinnGen IHD 69,101 cases vs AD 6,145, vascular 2,667, dementia 19,157 — and the true lipid→dementia effect is much smaller than lipid→IHD). The ANGPTL4 half deserved real caution, and got four specific reasons.

**Alex:** *but didn't we add a lot of cases from opengwas so the power should be good no?*
> **Alex was right, and Claude said so.** Two things had been conflated: *precision* (which the extra cases genuinely fixed) and *validity* (which they can't). For AD specifically we are now reasonably powered — PCSK9 meta 1.02 (0.93–1.13) isn't "underpowered", it's a **confident null**. The power argument survives only for all-cause / vascular / unspecified dementia, which got no OpenGWAS cases at all.

**Alex:** *what explains the likely difference for other null targets (statins, ezetimibe, etc) as compared to the study?*
> Reframed the comparison. We reproduced the paper's **two-sample** arm, so the fair benchmark is *their* 2SMR, not their headline. On that basis **5 of 6 targets are concordant** — including NPC1L1, which was **null in the paper's own 2SMR** (0.43, CI 0.14–1.33). The paper's confident dementia claims come from its one-sample and Cox arms, on ~1M individual-level participants.

**Alex:** *what is 2SMR*
> A plain-language primer: MR uses genetic variants as natural experiments; one-sample measures exposure and outcome in the *same* people (needs individual-level data — the arm we can't run); two-sample takes them from two different studies' summary statistics (which is what makes this reproducible at all).

**No files changed** — but this exchange is what produced the next commit.

---

## ⟲ Reflect — rebuild the report around what the questions exposed
`16-reflect-report-rewritten` · 2026-07-27 15:52

**Alex:**
> add to report the intro aboiut mendelian randomiztion, distinction between 2-sample and 1-sample. use fewer large tables of non-significant results and instead create a figure with the papers 2-sample results as well as ours and finally a figure with the papers 1-sample results and some text about why we didn't do 1-sample here

**What Claude did**

1. Two of the three changes could be made from data already in hand. The third — a figure of the **paper's one-sample results** — needed numbers that were never in `research.md`, because the Research phase had scoped it to *reproducible* facts only. So Claude went **back to the source PDF**.
2. `pdftotext` wasn't installed. Installed `poppler`, extracted the paper with `-layout`, and pulled the one-sample MR estimates for all six targets × {dementia, IHD} from the abstract and §3.3.
3. **Caught a units trap before drawing anything:** the paper's one-sample results are per **1 mmol/L** lower non-HDL, while our two-sample results are per **1 SD**. Not comparable in magnitude. The figure is explicitly labelled and captioned "compare directions, not sizes."
4. Rewrote `report.Rmd`:
   - a **"What is Mendelian randomization?"** primer — the natural-experiment intuition, the three instrument assumptions, and a one-sample vs two-sample table that explains *why* data availability scopes the whole project
   - **Figure**: our 2SMR vs the paper's 2SMR, dementia + IHD
   - **Figure**: the paper's one-sample arm, banner-flagged as not reproducible here
   - the large tables of non-significant results cut
5. Validated by knitting to markdown, then rendered to HTML.

**Files:** `report.Rmd`, `report.html`, `figure/*.png`

---

## ⟲ Reflect — define the jargon, explain the disagreement
`17-reflect-report-clarity` · 2026-07-27 16:13

**Alex:**
> in report when say IHD define it at least once, same for instrument. also for extension, if there is obvious reasons one of the larger studies disagrees with fingen, add explanation to text

**What Claude did**

1. **IHD defined at first mention** — the opening blockquote now reads "FinnGen dementia and **ischemic heart disease (IHD)** = outcome", anchoring every later use.
2. **"Instrument" defined at first mention**, placed immediately before the three instrument assumptions so the term is defined at the point it's first leaned on.
3. **Explained the source disagreement** using the sharpest real case — HMGCR, protective/null in FinnGen and Bellenguez but significantly *harmful* in Kunkle. Two concrete non-biological reasons:
   - **Single-instrument fragility** — the four one-SNP genes each rest on one variant's outcome association, so a sign flip between cohorts is expected sampling noise. The two multi-SNP genes are correspondingly stable across all three sources.
   - **Different AD phenotypes** — FinnGen is registry-diagnosed, Kunkle clinically adjudicated, and **Bellenguez adds by-proxy cases** (labelled by family history), a noisier and diluted phenotype. So systematic Bellenguez-vs-FinnGen gaps partly reflect *what "AD" means* in each study — which is also why the meta (clean Cochran's Q) is more trustworthy than any single source.
4. Re-rendered; re-confirmed the token still does not appear in the output.

*(One `Edit` in this step failed because its `old_string` didn't match the file — Claude grepped the actual text and retried successfully. The failed attempt is not in this history, only the correction.)*

**Files:** `report.Rmd`, `report.html`

---

## E · Execute — rebuild the report as a designed artifact
`18-execute-artifact` · 2026-07-27 17:38

**Alex:**
> recreate the report making it look nicer use the artifact-design skill and dataviz skill

**What Claude did**

1. **Loaded both skills before designing or writing anything** — they are required reading, not optional reference.
2. Read the dataviz reference palette, then followed the skill's non-negotiable rule: **run the validator, don't eyeball colorblind-safety.** The script is an ES module, which took three attempts to invoke correctly. Result: blue / orange / aqua pass in both light and dark; the one light-mode contrast WARN on aqua is covered by the relief rule (every figure ships a legend plus a **Table view** toggle).
3. Wrote a design plan before code, per the skill:
   - **Color** — cool clinical neutrals biased toward a petrol-teal accent (chrome only); validated `#2a78d6 / #eb6834 / #1baf7a` for data; a fully-designed dark theme, not an inversion
   - **Type** — scholarly serif display against a sans body with a mono for data, eyebrows and axis labels. System stacks only, so nothing can silently fall back under the artifact CSP. Deliberately *not* the cream/terracotta AI-cliché the skill warns about.
   - **Layout** — single-column reading article (~720px measure) with forest figures breaking out wider (~940px)
4. Wrote `report_artifact.html`: three **interactive inline-SVG forest plots** built to the skill's mark specs — 9px dots, 2px CI lines with caps, a surface ring on each point for overlap separation, a dashed OR = 1 reference, log axis, hover tooltips, per-figure table view.
5. Syntax-checked the embedded JavaScript with `node --check` before going further.

**Files:** `report_artifact.html`

---

## ⟲ Reflect — render it and actually look at it
`19-reflect-artifact-fixes` · 2026-07-27 17:40–17:45

*(no new prompt — Claude following the dataviz skill's final step: "render it and look at it")*

**What Claude did**

Screenshotted the page in headless Chrome and read the images back. Three rounds:

1. **First capture** — hero, tiles, cards and the two-panel forest all rendered cleanly. One real bug: the **single-panel chart scaled up ~2.5×**, so its gene labels were oversized against the two-panel figure. Fixed by giving single-panel charts a wider viewBox and capping their display width.
2. **Second capture came back blank.** The easy read is "screenshot artifact, ignore it." Claude read it as a **real robustness problem**: the scroll-reveal set `opacity: 0` until an IntersectionObserver fired, so the page's content *depended on JavaScript to be visible at all*, and the observer had raced the capture. Following the design skill's "less is more" guidance on motion, scroll-reveal was dropped entirely; only a self-completing CSS hero fade remains. Content is now always visible.
3. **Dark mode** showed a faint stray "LPL LPL" ghost. Rather than chase it, Claude tested the hypothesis: the capture had used Chrome's `--force-dark-mode`, which auto-darkens and can ghost text. Re-rendered through the **real** `data-theme` path — clean. Not a bug in the page.

Then published it as an Artifact (self-contained: system fonts, inline SVG/CSS/JS — nothing the CSP would block).

**Files:** `report_artifact.html`

---

## ⟲ Reflect — lead with the paper's headline, not ours
`20-reflect-headline-figure` · 2026-07-29 12:27

**Alex:**
> move the papers one-sample MR figure to top of report as it is the headline exciting peice from the paper

**What Claude did**

1. Checked both reports for the figure before editing, and found it in each: `report.Rmd` renders it from the paper's published numbers, and `report_artifact.html` draws it as inline SVG.
2. Moved the one-sample forest plot from its late "context" section to the **top of both reports**, reframed as *"The paper's headline result — not ours."* The framing is the point: it's the ~70–80% lower dementia odds via HMGCR / NPC1L1 / CETP that the paper's ~500k-person individual-level arm delivers, and it is explicitly labelled as the paper's numbers.
3. Left the "why we did not reproduce the one-sample arm" section where it was, minus the figure, and made it **cross-link back to the top**.
4. Kept the units warning attached to the figure in its new position — one-sample is per 1 mmol/L, our two-sample is per 1 SD.
5. Re-knit `report.html` from the `.Rmd` and verified both cross-link anchors resolve in the rendered output.

**Why this is the right structure:** the reader now sees the claim the project set out to chase *before* seeing the reproduction, and understands from the first screen which part was in reach and which wasn't.

**Files:** `report.Rmd`, `report.html`, `report_artifact.html`

---

## ⟲ Reflect — "divergence" was the wrong word
`21-reflect-cetp-attenuated` · 2026-07-29 13:20

**Alex:**
> this seems wrong: "the lone real divergence is CETP — and since our CETP→IHD matches the paper, the gap points at the FinnGen dementia outcome, not the instrument." the cetp result is the same direction as paper just not significant so its not an divergence at all

**What Claude did**

Alex was right, and it mattered. Claude checked all six dementia estimates against the paper rather than just fixing the sentence:

| | Ours | Paper |
|---|---|---|
| HMGCR | 0.70 | 0.59 |
| NPC1L1 | 0.83 | 0.43 |
| PCSK9 | 1.02 | 1.03 |
| ANGPTL4 | 1.43 | 1.08 |
| LPL | 1.70 | 1.60 |
| CETP | 0.84 | 0.54 |

**Same side of 1 in every case** — so directional concordance is **6 / 6**, not 5 / 6. CETP is *attenuated* and loses significance; it does not disagree.

The claim had propagated to four places, and grepping found all of them:

| Where | Was | Now |
|---|---|---|
| Artifact stat tile | Concordance **5 / 6** | **6 / 6** |
| Artifact body text | "the lone real divergence is CETP" | same direction, attenuated 0.54 → 0.84, no longer significant |
| Artifact figure caption | "CETP dementia is the one genuine divergence" | "attenuated toward the null, CETP most of all" |
| `report.Rmd` caption + body | "Direction agrees for 5/6" | all six agree; CETP is the largest attenuation |

The artifact had also been **self-contradictory** — it said "the *directions* agree everywhere" one clause before calling CETP a divergence. Re-knit `report.html` and redeployed the hosted artifact.

**One further caveat surfaced, unprompted:** `report.Rmd` names HMGCR / LPL / CETP as the paper's significant dementia targets, but ours reaches significance only for LPL (p = 0.0495) — so HMGCR lost significance too, not just CETP.

**Files:** `report.Rmd`, `report.html`, `report_artifact.html`

---

## Where it ended up

- `Rscript run_phase1.R` · `run_phase2.R` · `run_phase3.R` — the whole pipeline, from cached data, no manual steps
- `report.Rmd` → `report.html` — the knittable narrative report
- `report_artifact.html` — the designed, interactive version
- 6 drug-target genes × 4 outcomes × 3 exposures × 5 estimators, with the IHD positive control passing at every stage
